Supplementary Appendix
This appendix has been provided by the authors to give readers additional information about their work. Table S1 . Individuals examined and treated and number of AEs per village by health area 2) Figure S1 . Principle of use and output of LoaScope Figure S1 . Principle of use and outputs of LoaScope. Figure S2 . Location of the 92 villages included in the TaNT survey with Ov16 prevalence. Figure S3 . Timeline of the Test and not Treat strategy during year 2015 Figure S4 . Individual card given to all participants 696 50 51 85 Figure S5 . Standardized form to record all adverse events following ivermectin treatment Figure S6 . Number of excluded individuals in each village, classified by cause of exclusion (high Loa microfilaremia or other cause)
